Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse | Leukemia
Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients - ScienceDirect
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma | Advances in Therapy
The Evolving Clinical and Pharmacoeconomic Impact of Isatuximab in Multiple Myeloma Management | Value-Based Cancer Care
FDA
Subcutaneous daratumumab plus pomalidomide and dexamethasone in R/R MM - Medical Conferences
British Journal of Haematology | Wiley Online Library
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma | NEJM
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma - Zhou - 2020 - Cancer Medicine - Wiley Online Library
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma | Advances in Therapy
Newly Diagnosed: D + VTD Treatment | DARZALEX® IV (daratumumab)
Daratumumab and hyaluronidase-fihj (Darzalex Faspro) Drug Info
Multiple Myeloma Support + Trials
APOLLO trial results: Addition of daratumumab to pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology
APOLLO Study | Int'l Myeloma Foundation
Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials | Scientific Reports
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial - The
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology
Subcutaneous daratumumab plus pomalidomide-dexamethasone: an effective treatment option for MM - BJH
Relapsed: D + PD Treatment | DARZALEX® IV (daratumumab)
Pharmaceuticals | Free Full-Text | Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
